Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
enGene Holdings ( (ENGN) ) has shared an announcement.
enGene has changed its corporate name from enGene Holdings Inc. to enGene Therapeutics Inc., underscoring its shift from a development-focused biotechnology firm toward a potential commercial-stage organization as it advances its lead bladder cancer gene therapy. The company is preparing for a planned Biologics License Application submission for detalimogene voraplasmid in the second half of 2026, targeting possible approval in 2027, while its Nasdaq ticker symbols remain unchanged and security holders’ rights are unaffected despite new CUSIP and ISIN identifiers.
detalimogene is being studied in the LEGEND trial for high-risk non-muscle invasive bladder cancer, including BCG-unresponsive carcinoma in situ, a patient group with high recurrence rates and limited treatment options short of bladder removal. The therapy has secured RMAT and Fast Track designations, as well as inclusion in the FDA’s CMC Development and Readiness Pilot program, positioning enGene to potentially accelerate regulatory review and commercial readiness in a market with significant unmet medical need and substantial healthcare cost implications.
The most recent analyst rating on (ENGN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, inconsistent profitability, and substantial ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD and very low RSI/stochastics). A low P/E and a relatively strong balance sheet provide partial support but do not offset the operating and cash-flow risks.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines, with a primary focus on gene therapies for high-risk non-muscle invasive bladder cancer. Its lead investigational product, detalimogene voraplasmid, uses the company’s Dually Derivatized Oligochitosan platform to deliver localized anti-tumor immune responses and aims to offer an alternative to viral-based gene therapies in urologic oncology.
Average Trading Volume: 429,794
Technical Sentiment Signal: Sell
Current Market Cap: $485M
Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.